CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the publication of results from the Company’s U.S. CytoSorb Therapy in COVID-19 (CTC) retrospective registry in the peer-reviewed journal, Frontiers in Medicine.
The new publication highlights 52 critically ill COVID-19 patients from 5 major U.S. ECMO (ExtraCorporeal Membrane Oxygenation) centers who received ECMO plus CytoSorb therapy for life-threatening refractory respiratory failure under FDA EUA between April 2020 and April 2021.1 As highlighted in topline results that were previously presented at the 40th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2021) conference in September, the primary outcome of 90-day ICU mortality was 26.9% from the initiation of CytoSorb treatment. For context, 90-day mortality among more than 6,400 adult patients in the North American cohort of the Extracorporeal Life Support Organization (ELSO) COVID-19 ECMO Registry is 50% (as of December 2021). Importantly, all 5 centers participating in the CTC registry reported that CytoSorb was easily integrated in the ECMO circuit and well-tolerated, with no unanticipated device-related adverse events.
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “We are pleased that this important data set showing high survival in critically ill COVID-19 patients on CytoSorb and ECMO in the U.S. has been peer-reviewed, published, and is now available to all current and potential users globally. This is especially important, in light of increasing COVID-19 related new cases and deaths being observed around the world driven by the Delta variant, and the threat of new variants such as Omicron. To date, CytoSorb has been used in more than 7,000 critically ill COVID-19 patients in more than 30 countries worldwide, including in the U.S. under FDA Emergency Use Authorization.”